Citations 3
Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
Forero‐Torres, Andres , Sher, Taimur , Scherle, Peggy , Schaub, Richard, Zhou, Li , Pulini, Jennifer, Leopold, Lance, Spear, Matthew A. , Phillips, Tycel , Diefenbach, Catherine , Talpaz, Moshe , Barr, Paul M.
Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8520-8520
A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Forero‐Torres, Andres , Sher, Taimur , Schaub, Richard, Zhou, Li , Pulini, Jennifer, Leopold, Lance, Spear, Matthew A. , Barr, Paul M. , Diefenbach, Catherine , Talpaz, Moshe , Phillips, Tycel
Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8558-8558
A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Sher, Taimur , Lebovic, Daniel, Zhou, Li , Pulini, Jennifer, Spear, Matthew A. , Forero‐Torres, Andres , Barr, Paul M. , Phillips, Tycel
Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8607-TPS8607